SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CMTR-CHEMTRAK FDA OK -- Ignore unavailable to you. Want to Upgrade?


To: Ipso facto who wrote (1142)11/23/1998 7:32:00 PM
From: Mr. E  Read Replies (1) | Respond to of 1172
 
SUNNYVALE, Calif.--(BUSINESS WIRE)--April 30, 1998--ChemTrak Inc. (Nasdaq:CMTR) Thursday announced that it has raised approximately  $1 million from the private placement of redeemable convertible preferred B stock.

This placement is the first of two tranches.  The preferred B shares are convertible into common stock 90 days after closing.  The preferred stock bears cumulative dividends at an annual rate of  6 percent, payable in shares of common stock or cash at the company's option.

The preferred B shares, after adjustment to account for any accrued dividend that has not been paid in cash, is convertible at a conversion price equal to the lower of (1) 100 percent of the five-day Nasdaq average closing-bid price on the date of each individual closing, or (2) 75 percent of the five-day average Nasdaq closing-bid price at time of conversion.

An additional tranche of up to $2 million convertible preferred B is expected to close later in the second quarter.  In February 1998, the company announced the private placement of $1.3 million of convertible preferred A shares.



To: Ipso facto who wrote (1142)11/23/1998 8:05:00 PM
From: Mr. E  Read Replies (1) | Respond to of 1172
 
pentechfinancial.com. Link to info on funding.
No where have I been able to find a connection between Alexander, Wescott & Co. or Bach & Co.
Where are you getting your information?